Only the lowest THC dose helped schizophrenia-like symptoms in rats, while higher doses made them worse | Research

The takeaway

In a rat model of schizophrenia, only the lowest THC dose (0.1 mg/kg) reversed social withdrawal deficits, while moderate and higher doses produced schizophrenia-like symptoms in healthy rats.

Schizophrenia researchers, psychopharmacologists, and clinicians studying cannabis-psychosis interactions.

Only 0.1 mg/kg THC helped; higher doses produced schizophrenia-like symptoms

What the researchers found

In PCP-treated rats (schizophrenia model), only the lowest THC dose (0.1 mg/kg) reversed social interaction deficits and normalized elevated anandamide in the nucleus accumbens. Higher THC doses (0.3, 1.0 mg/kg) did not help. In control rats, THC dose-dependently produced social deficits and aberrant VTA dopamine neuron activity resembling schizophrenia. THC activated the Akt/GSK3β pathway dose-dependently in both groups.

Why it matters

This provides the clearest preclinical demonstration of why cannabis has seemingly contradictory effects on schizophrenia: extremely low doses may be therapeutic while typical recreational doses are harmful. The dose-response curve is not linear but inverted U-shaped.

The numbers in context

0.1 mg/kg THC: reversed social deficits in PCP rats and normalized AEA; 0.3-1.0 mg/kg: no benefit; in controls, THC dose-dependently produced social deficits and aberrant dopamine activity; Akt/GSK3β activated dose-dependently.

How the study worked

Sub-chronic PCP rat model with THC at 0.1, 0.3, and 1.0 mg/kg. Assessed social interaction, amphetamine-induced motor activity, VTA dopamine neuron population activity, endocannabinoid levels, and Akt/GSK3β signaling.

What this study cannot tell us

Animal model of schizophrenia (PCP model has limitations); narrow dose range tested; acute THC (does not model chronic use); rat-to-human dose translation uncertain; cannot confirm same inverted U-curve applies to humans.

How to read the evidence

Preliminary: single animal study with interesting dose-response, but PCP model limitations and unknown human translation.

When this study was published

Published 2020.

The bigger picture

The self-medication hypothesis for cannabis use in schizophrenia has been controversial. This study suggests it may be partially correct: patients might experience benefit from very low cannabinoid exposure, but typical cannabis use delivers doses that worsen the condition.

Questions still open

Is there a human THC microdose that could help schizophrenia negative symptoms? Would CBD preserve the low-dose benefit while preventing high-dose harm?

Common questions

Can THC help or hurt schizophrenia?

Both, depending on dose. In this rat model, only the very lowest THC dose reversed schizophrenia-like social withdrawal. Higher doses made things worse and even created schizophrenia-like symptoms in normal rats.

Does this explain why people with schizophrenia use cannabis?

Possibly. Very low cannabinoid levels may provide temporary relief of negative symptoms (social withdrawal), but typical recreational doses likely worsen the condition. This could create a cycle where patients initially benefit but eventually deteriorate.

Read the original research

Differential effects of Δ9-tetrahydrocannabinol dosing on correlates of schizophrenia in the sub-chronic PCP rat model.

PloS one, 15(3), e0230238

View on PubMed ↗Publisher’s paper ↗

Citation

Seillier, Alexandre; Martinez, Alex A; Giuffrida, Andrea. (2020). Differential effects of Δ9-tetrahydrocannabinol dosing on correlates of schizophrenia in the sub-chronic PCP rat model.. PloS one, 15(3), e0230238. https://doi.org/10.1371/journal.pone.0230238